S. Danese and C. Fiocchi, Ulcerative Colitis, New England Journal of Medicine, vol.365, issue.18, pp.1713-1738, 2011.
DOI : 10.1056/NEJMra1102942

URL : https://hal.archives-ouvertes.fr/hal-01303796

A. Dignass, R. Eliakim, and F. Magro, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis, Journal of Crohn's and Colitis, vol.6, issue.10, pp.965-90, 2012.
DOI : 10.1016/j.crohns.2012.09.003

A. Dignass, J. Lindsay, and A. Sturm, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management, Journal of Crohn's and Colitis, vol.6, issue.10, pp.991-1030, 2012.
DOI : 10.1016/j.crohns.2012.09.002

F. Bär, C. Sina, and K. Fellermann, Thiopurines in inflammatory bowel disease revisited, World Journal of Gastroenterology, vol.19, issue.11, pp.1699-706, 2013.
DOI : 10.3748/wjg.v19.i11.1699

B. Feagan, P. Rutgeerts, and B. Sands, Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.369, issue.8, pp.699-710, 2013.
DOI : 10.1056/NEJMoa1215734

A. Saniabadi, T. Tanaka, T. Ohmori, K. Sawada, T. Yamamoto et al., Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs, World Journal of Gastroenterology, vol.20, issue.29, pp.9699-715, 2014.
DOI : 10.3748/wjg.v20.i29.9699

M. Vecchi, P. Vernia, G. Riegler, D. Incà, R. Annese et al., Therapeutic landscape for ulcerative colitis: where is the Adacolumn® system and where should it be?, Clinical and Experimental Gastroenterology, vol.6, pp.1-7, 2013.
DOI : 10.2147/CEG.S33275

T. Matsumoto, A. Andoh, and K. Okawa, Multivariate Analysis for Factors Predicting Rapid Response of Leukocytapheresis in Patients With Steroid-resistant Ulcerative Colitis: A Multicenter Prospective Open-label Study, Therapeutic Apheresis and Dialysis, vol.165, issue.Suppl. 1, pp.484-90, 2008.
DOI : 10.1111/j.1744-9987.2008.00639.x

H. Hanai, Y. Takeda, and M. Eberhardson, The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review, Clinical & Experimental Immunology, vol.23, issue.2, pp.50-58, 2011.
DOI : 10.1111/j.1365-2249.2010.04279.x

N. Kashiwagi, I. Hirata, and R. Kasukawa, A Role for Granulocyte and Monocyte Apheresis in the Treatment of Rheumatoid Arthritis, Therapeutic Apheresis, vol.100, issue.1, pp.134-175, 1998.
DOI : 10.1111/j.1744-9987.1998.tb00091.x

A. Saniabadi, H. Hanai, and K. Takeuchi, Adacolumn, an Adsorptive Carrier Based Granulocyte and MonocyteApheresis Device for the Treatment of Inflammatory and RefractoryDiseases Associated with Leukocytes, Therapeutic Apheresis and Dialysis, vol.52, issue.1, pp.48-59, 2003.
DOI : 10.1016/0014-5793(95)01036-E

B. Habermalz and S. Sauerland, Clinical Effectiveness of Selective Granulocyte, Monocyte Adsorptive Apheresis with the Adacolumn?? Device in Ulcerative Colitis, Digestive Diseases and Sciences, vol.8, issue.Suppl 1, pp.1421-1429, 2010.
DOI : 10.1007/s10620-009-0845-x

S. Thanaraj, P. Hamlin, and A. Ford, Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.327, issue.11-12, pp.1297-306, 2010.
DOI : 10.1111/j.1365-2036.2010.04490.x

URL : https://hal.archives-ouvertes.fr/hal-00585782

M. Zhu, X. Xu, F. Nie, J. Tong, S. Xiao et al., The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis, International Journal of Colorectal Disease, vol.2, issue.8, pp.999-1007, 2011.
DOI : 10.1007/s00384-011-1193-9

J. Cabriada, E. Domènech, and N. Ibargoyen, Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry, Journal of Gastroenterology, vol.1, issue.4, pp.359-65, 2012.
DOI : 10.1007/s00535-011-0499-2

W. Kruis, A. Dignass, and E. Steinhagen-thiessen, Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis, World Journal of Gastroenterology, vol.11, issue.44, pp.7001-7007, 2005.
DOI : 10.3748/wjg.v11.i44.7001

D. Rachmilewitz, Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial., BMJ, vol.298, issue.6666, pp.82-88, 1989.
DOI : 10.1136/bmj.298.6666.82

T. Yamamato, S. Umegae, and K. Matsumoto, Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis, World Journal of Gastroenterology, vol.12, issue.4, pp.520-525, 2006.
DOI : 10.3748/wjg.v12.i4.520

H. Hjortswang, G. Järnerot, and B. Curman, The Short Health Scale: A valid measure of subjective health in ulcerative colitis, Scandinavian Journal of Gastroenterology, vol.4, issue.10, pp.1196-203, 2006.
DOI : 10.1136/bmj.281.6240.581

F. Lehmann, E. Burri, and C. Beglinger, The role and utility of faecal markers in inflammatory bowel disease, Therapeutic Advances in Gastroenterology, vol.8, issue.1, pp.23-36, 2015.
DOI : 10.1177/1756283X14553384

A. Dignass, A. Eriksson, A. Kilander, A. Pukitis, J. Rhodes et al., Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.41, issue.12, pp.1286-95, 2010.
DOI : 10.1111/j.1365-2036.2010.04295.x

URL : https://hal.archives-ouvertes.fr/inserm-00668856

B. Sands, W. Sandborn, and B. Feagan, A Randomized, Double-Blind, Sham-Controlled Study of Granulocyte/Monocyte Apheresis for Active Ulcerative Colitis, Gastroenterology, vol.135, issue.2, pp.400-409, 2008.
DOI : 10.1053/j.gastro.2008.04.023

W. Kruis, P. Nguyen, and M. J. Granulocyte, Granulocyte/Monocyte Adsorptive Apheresis in Moderate to Severe Ulcerative Colitis - Effective or Not, Digestion, vol.92, issue.1, pp.39-44, 2015.
DOI : 10.1159/000431149

J. Rahier, S. Ben-horin, and Y. Chowers, European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, Journal of Crohn's and Colitis, vol.3, issue.2, pp.47-91, 2009.
DOI : 10.1016/j.crohns.2009.02.010

C. Siegel, S. Marden, S. Persing, R. Larson, and B. Sands, Risk of Lymphoma Associated With Combination Anti???Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis, Clinical Gastroenterology and Hepatology, vol.7, issue.8, pp.874-81, 2009.
DOI : 10.1016/j.cgh.2009.01.004

S. Kane, D. Brixner, D. Rubin, and M. Sewitch, The Challenge of Compliance and Persistence: Focus on Ulcerative Colitis, Journal of Managed Care Pharmacy, vol.14, issue.1 Supp A, pp.2-12, 2008.
DOI : 10.18553/jmcp.2008.14.S1-A.1a

E. Irvine, Patients' fears and unmet needs in inflammatory bowel disease, Alimentary Pharmacology and Therapeutics, vol.358, issue.9286, pp.54-63, 2004.
DOI : 10.1016/0163-8343(96)00036-9

J. Satsangi, M. Silverberg, S. Vermeire, and J. Colombel, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006.
DOI : 10.1136/gut.2005.082909